The Uromigos

Health EN ↓ 478 episodes

Broadcasting the latest developments in GU cancerHosted by Brian Rini and Tom Powles Brian Rini MD is an Ingram Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer CenterTom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London

Author

The Uromigos

Episodes

Episode 104: Plenary Session 177lu-PSMA-617 in Prostate Cancer 06.06.2021 30:29

Mike Morris does his stuff. 

Episode 103: Targeting the microbiome to increase the activity of immune therapy in renal cancer 06.06.2021 13:31

Monty Pal describes a small randomised trial of ipi/nivo plus CMB588.

Episode 102: Adjuvant therapy in melanoma - how it will help inform the renal community 28.05.2021 29:05

James Larkin describes learning from adjuvant immune checkpoint inhibitors in melanoma. 

Episode 101: The Uromigos Paper of the Month - Belzutifan in renal cancer 26.05.2021 26:59

Eric Jonasch gives an overview of the recent Nature Medicine publication. 

Episode 100: The Uromigos 100th Podcast - Looking to the Future 21.05.2021 36:24

Chris Sweeney, Kala Sridhar and David McDermott discuss the future. 

Episode 99: Navigating social media from a patients' perspective 19.05.2021 24:58

Dena Battle is the co-founder and president of KCure and a passionate kidney cancer patient advocate. 

Episode 98: Bladder cancer from a patient perspective 19.05.2021 23:35

Dr. Lydia Makaroff, Vice President of the World Bladder Cancer Patient Coalition, discusses key issues for bladder cancer. 

Episode 97: Sacituzumab Govitecan in Bladder Cancer 04.05.2021 18:21

Petros Grivas discusses the recent accelerated approval and JCO paper data.

Episode 96: ODAC Bladder Cancer Accelerated Approval Meetings with Andrea Apolo 28.04.2021 26:23

Andrea Apolo discusses highlights from the April 28th meeting. 

Episode 95: ODAC Overview and Bladder Accelerated Approval Meetings with Jorge Garcia 28.04.2021 26:55

Jorge Garcia discusses the pembrolizumab and atezolizumab bladder cancer dangling accelerated approvals and the ODAC process

Episode 94: EIKCS Summary of Day 1 23.04.2021 24:40

Samra Turajlic summarised the meetings and looks forward to Day 2...

Episode 93: The Uromigos Paper of the Month - A new risk classification for germ cell cancer 14.04.2021 23:49

Silke Gillessen discusses the back to back JCO papers on this topic. 

Episode 92: Second line therapy in advanced RCC 09.04.2021 27:31

Viktor Grünwald discusses treatment for progression of disease after front lines PD1 based therapy. 

Episode 91: The Uromigos Paper of the Month - Adjuvant atezolizumab in bladder cancer 26.03.2021 29:05

Joaquim Bellmunt describes this study as well as adjuvant nivolumab and ctDNA in bladder cancer. 

Episode 90: The Uromigos Podcast with QOL Expert David Cella 12.03.2021 27:46

Everything you wanted to know about quality of life assessment in cancer but were too afraid to ask. 

Episode 89: The Uromigos Paper of the Month - Pembrolizumab in clear cell and non-clear cell renal cancer 04.03.2021 28:14

David McDermott describes these back to back JCO publications. 

Episode 88: Career Development in Academic Oncology Part 3 - Walter Stadler 26.02.2021 23:14

In these podcasts, we explore academic career development with individuals in different stages of their career. 

Episode 87: Career Development in Academic Oncology Part 2 - Monty Pal 26.02.2021 22:17

In these podcasts, we explore academic career development with individuals at different stages in their career. 

Episode 86: Career Development in Academic Oncology Part 1 - Moshe Ornstein 26.02.2021 20:55

In these podcasts, we explore academic career development with individuals in different stages of their career. 

Episode 85: The CLEAR Trial 14.02.2021 29:42

Toni Choueiri discusses the phase three results

Episode 84: Prostate cancer highlights from ASCO #GU21 with Chris Sweeney 13.02.2021 17:24

Chris explores the prostate cancer programme. 

Episode 82: Which is the best VEGF/immune combination for first line metastatic renal cancer? 13.02.2021 24:40

Eric Jonash gives a thoughtful answer to this issue. 

Episode 83: Is cabozantinib the new standard of care in papillary renal cancer? 13.02.2021 21:54

Monty Pal discusses his randomised phase 2 study in papillary renal cancer. 

Episode 81: Noah Hahn discusses front line cisplatin-ineligible PD-L1 data from 361 and 130 13.02.2021 21:22

These new data are important as it is the setting where these agents are currently recommended, but we have not seen the data in this specific subset until now. 

Episode 80: Results for Darolutamide in non-metastatic CRPC - the Aramis trial 13.02.2021 19:52

Neil Shore presents the impressive updates for the results of this trial. 